The Deep Integration Of Stereotactic Biopsy And Molecular Pathology

Core Perspective:​ Focusing on the relationship between tissue sample quality and downstream analysis, this article discusses how stereotactic core needle biopsy provides high-quality starting material for genetic testing, molecular subtyping, and individualized treatment of breast cancer.

The treatment of breast cancer has entered the era of precision medicine. Therapeutic regimens are no longer dictated solely by tumor size and lymph node status but depend primarily on molecular subtypes (such as Luminal A/B, HER2 overexpression, and Triple-Negative). The source of this vital information is the minute tissue sample obtained through biopsy. Breast Stereotactic Core Needle Biopsy serves as the critical bridge connecting macroscopic imaging diagnosis with microscopic molecular pathological analysis.

Unlike traditional Fine Needle Aspiration (FNA), which only yields cytological samples, stereotactic core needle biopsy-particularly when utilizing 14G or 12G vacuum-assisted biopsy systems-procures intact tissue cores. These cores preserve the complete tissue architecture, allowing for formalin fixation, paraffin embedding, and sectioning. This facilitates standard Hematoxylin and Eosin (H&E) staining, Immunohistochemical (IHC) staining (e.g., ER, PR, Ki-67), and in situhybridization (e.g., HER2 FISH). This histological-level diagnosis is far more reliable than cytology, as it can distinguish between in situand invasive carcinoma-a cornerstone for formulating treatment plans.

More importantly, high-quality biopsy tissue is the prerequisite for genomics and proteomics analysis. For instance, in advanced or recurrent metastatic breast cancer, physicians require biopsy samples for Next-Generation Sequencing (NGS) to identify potential driver gene mutations (e.g., PIK3CA, ESR1) to match targeted therapies. Stereotactic biopsies yield an ample volume of tissue with high cellular viability and minimal RNA/DNA degradation, perfectly satisfying the requirements for these highly sensitive assays.

Furthermore, stereotactic biopsy has catalyzed comparative studies with "liquid biopsy." By comparing the genetic profile of the tissue biopsy with the results of circulating tumor DNA (ctDNA) in the patient's blood, scientists can validate the accuracy of non-invasive testing. This paves the way for potentially monitoring treatment efficacy and drug resistance through a simple blood draw in the future.

Therefore, the value of Stereotactic Core Needle Biopsy extends far beyond determining "benign or malignant." It is the key that unlocks the door to precision therapy. Every successful stereotactic biopsy contributes to drawing a unique "molecular portrait" of the patient's tumor. This portrait guides the physician in selecting the most effective chemotherapy, endocrine therapy, or targeted drugs, truly realizing the goal of "treatment tailored to the individual."